ABVX
Abivax S.A. NASDAQ Listed Oct 20, 2023$99.15
-1.00%
vs $100.15
Mkt Cap $6.5B
52w Low $5.69
65.3% of range
52w High $148.83
50d MA $114.34
200d MA $110.98
P/E (TTM)
-21.3x
EV/EBITDA
—
P/B
15.2x
Debt/Equity
0.1x
ROE
—
P/FCF
-44.2x
RSI (14)
35.50
ATR (14)
$7.75
Beta
-0.10
50d MA
$114.34
200d MA
$110.98
Avg Volume
2.4M
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
5, rue de la Baume · Paris 75008 · FR
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -1.07 | -1.22 | -13.8% | 115.42 | +0.6% | -4.5% | +0.5% | -1.1% | -6.4% | -0.9% | — |
| Sep 8, 2025 | AMC | -0.90 | -0.86 | +4.4% | 90.00 | -0.7% | -0.8% | -1.8% | -1.9% | -2.3% | +2.2% | — |
| Mar 24, 2025 | AMC | -0.68 | -1.55 | -128.0% | 7.37 | +2.3% | -0.4% | -3.4% | -3.8% | -5.7% | -2.8% | — |
| Nov 7, 2024 | AMC | -1.28 | -0.70 | +45.5% | 10.54 | -2.2% | -0.7% | +0.8% | -2.1% | -1.5% | -2.2% | — |
| Apr 2, 2024 | AMC | -0.91 | -1.94 | -112.7% | 14.04 | +1.1% | +6.4% | +0.0% | -0.5% | +1.5% | -1.3% | — |
| Jun 30, 2023 | AMC | — | -1.58 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2 | Wedbush | Upgrade | Underperform → Neutral | $90 | $129.69 | $77.53 | -40.2% | -44.1% | +24.3% | +16.4% | -3.2% | +0.0% |
| Jun 2 | Jefferies | Downgrade | Buy → Hold | $90 | $129.69 | $77.53 | -40.2% | -44.1% | +24.3% | +16.4% | -3.2% | +0.0% |
| Mar 24 | Barclays | Maintains | Overweight → Overweight | — | $115.42 | $116.16 | +0.6% | -4.5% | +0.5% | -1.1% | -6.4% | -0.9% |
| Feb 25 | BTIG | Maintains | Buy → Buy | — | $128.29 | $125.70 | -2.0% | -3.9% | -3.1% | +1.5% | -6.7% | -1.8% |
| Jan 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $115.49 | $118.62 | +2.7% | -0.9% | +3.1% | +1.4% | +4.5% | -6.6% |
| Jan 8 | BTIG | Maintains | Buy → Buy | — | $126.48 | $125.10 | -1.1% | -8.7% | -0.9% | +3.1% | +1.4% | +4.5% |
| Dec 16 | Citizens | Maintains | Market Outperform → Market Outperform | — | $117.91 | $113.00 | -4.2% | -5.9% | -0.1% | +2.5% | +1.2% | +20.7% |
| Oct 10 | Guggenheim | Maintains | Buy → Buy | — | $90.61 | $93.71 | +3.4% | +3.5% | +2.0% | +2.3% | -2.3% | -2.8% |
| Oct 7 | BTIG | Maintains | Buy → Buy | — | $86.67 | $87.32 | +0.8% | +0.4% | -0.6% | +4.7% | +3.5% | +2.0% |
| Sep 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $82.55 | $83.00 | +0.5% | -0.7% | +1.0% | +0.6% | +1.9% | -2.9% |
| Sep 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $85.96 | $83.00 | -3.4% | -2.3% | +2.2% | -4.2% | -1.6% | +2.9% |
| Sep 9 | BTIG | Maintains | Buy → Buy | — | $90.00 | $89.40 | -0.7% | -0.8% | -1.8% | -1.9% | -2.3% | +2.2% |
| Jul 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $66.57 | $67.00 | +0.6% | +4.9% | +1.5% | +1.3% | +0.2% | +0.2% |
| Jul 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $10.00 | $63.10 | +531.0% | +586.0% | +1.7% | -4.7% | +0.1% | +4.9% |
| Jul 23 | LifeSci Capital | Maintains | Outperform → Outperform | — | $10.00 | $63.10 | +531.0% | +586.0% | +1.7% | -4.7% | +0.1% | +4.9% |
| Jul 23 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $10.00 | $63.10 | +531.0% | +586.0% | +1.7% | -4.7% | +0.1% | +4.9% |
| Jul 23 | Guggenheim | Maintains | Buy → Buy | — | $10.00 | $63.10 | +531.0% | +586.0% | +1.7% | -4.7% | +0.1% | +4.9% |
| Jul 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.00 | $63.10 | +531.0% | +586.0% | +1.7% | -4.7% | +0.1% | +4.9% |
| Apr 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.12 | $7.51 | +5.5% | +0.0% | -2.9% | +4.1% | -1.0% | -5.2% |
| Mar 18 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $6.00 | $6.54 | +9.0% | +13.3% | +0.6% | +3.2% | +4.5% | -0.1% |
| Jan 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.68 | $6.80 | +1.8% | -4.5% | +1.9% | -5.4% | +2.3% | -1.0% |
| Apr 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $15.39 | $15.81 | +2.7% | -2.5% | +0.0% | -2.0% | +0.2% | +1.0% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 6,303,988 | $850M | Added | Dec 2025 |
| 2 | Ubs Group Ag | 4,547,406 | $506M | Added | Mar 2026 |
| 3 | Adar1 Capital Management, Llc | 1,394,019 | $155M | New | Mar 2026 |
| 4 | Fmr Llc | 1,286,373 | $143M | Reduced | Mar 2026 |
| 5 | Janus Henderson Group Plc | 878,829 | $98M | New | Mar 2026 |
| 6 | Lord, Abbett & Co. Llc | 854,920 | $95M | Added | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 735,729 | $82M | Added | Mar 2026 |
| 8 | Point72 Asset Management | 637,736 | $71M | Reduced | Mar 2026 |
| 9 | Ensign Peak Advisors, Inc | 631,838 | $70M | Added | Mar 2026 |
| 10 | Millennium Management | 605,992 | $67M | Reduced | Mar 2026 |
| 11 | Jpmorgan Chase & Co | 635,066 | $64M | Added | Mar 2026 |
| 12 | Citadel Advisors Llc | 544,338 | $61M | Reduced | Mar 2026 |
| 13 | Jane Street Group, Llc | 423,257 | $57M | Added | Dec 2025 |
| 14 | Silverarc Capital Management, Llc | 422,193 | $57M | Reduced | Dec 2025 |
| 15 | Aberdeen Group Plc | 431,241 | $48M | Added | Mar 2026 |
| 16 | Franklin Resources Inc | 382,830 | $43M | Reduced | Mar 2026 |
| 17 | Susquehanna International Group, Llp | 381,282 | $42M | Reduced | Mar 2026 |
| 18 | Stempoint Capital Lp | 313,791 | $35M | New | Mar 2026 |
| 19 | Principal Financial Group Inc | 217,890 | $29M | New | Dec 2025 |
| 20 | Hudson Bay Capital Management Lp | 208,219 | $28M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$6.50B
Enterprise Value
$6.39B
P/E (TTM)
-21.32x
Forward P/E
—
PEG Ratio
-0.37x
P/B
15.15x
P/S
—
P/FCF
-44.24x
EV/EBITDA
—
Shares Out
69.5M
Financials (TTM)
Revenue
$0
Net Income
-$322.8M
EBITDA
-$239.7M
Free Cash Flow
-$155.8M
Op Cash Flow
-$155.7M
EPS Basic
$-4.65
EPS Diluted
$-4.65
EPS Forward
$-3.51
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$584.1M
Total Liab.
$129.1M
Total Equity
$455.0M
Cash
$530.2M
LT Debt
$30.2M
Book Value/Sh
$6.54
Debt/Equity
0.07x
Current Ratio
8.75
Quick Ratio
8.75
Returns & Growth
ROE
—
ROA
—
ROIC
-46.1%
Rev Growth YoY
-100.0%
EPS Growth YoY
-66.1%
Price Returns
2W
+9.6%
1M
+13.0%
3M
+9.4%
6M
+6.2%
12M
+2103.2%
Technicals
52W High
$148.83
52W Low
$5.69
50d MA
$114.34
200d MA
$110.98
RSI (14)
35.50
ATR (14)
$7.75
Beta
-0.10
Avg Volume
2.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$146.13
High
$176.00
Low
$110.00
Median
$143.50
Data updated apr 26, 2026 9:26am
· Source: financialmodelingprep.com